• Second quarter revenues increased 6% (+5% Ex-FX) to $13.0 billion
◦ Growth Portfolio revenues increased 15% (+14% Ex-FX) to $7.6 billion
• GAAP EPS was $1.62 and non-GAAP EPS was $2.04
• Raising 2026 revenue guidance to a range of ~$49.0 billion to $50.0 billion; Increasing non-GAAPEPS range to $6.75 to $7.00
(PRINCETON, N.J., July 30, 2026) – Bristol Myers Squibb (NYSE: BMY) today reports results for thesecond quarter of 2026.
“The Growth Portfolio continues to deliver, achieving 15% growth in the quarter, and represents anexpanding share of our overall business," said Christopher Boerner, Ph.D., board chair and chiefexecutive officer, Bristol Myers Squibb. "We are building from a position of strength and progressinga differentiated pipeline designed to generate long-term value. As a result of our consistentexecution and continued momentum, we are raising our 2026 full-year outlook."
SECOND QUARTER RESULTS*
• Growth Portfolio revenues of $7.6 billion increased 15%, or 14% Ex-FX. Revenue growth wasprimarily driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag.
• Legacy Portfolio revenues of $5.4 billion decreased 4%, or 5% Ex-FX. Demand increased forEliquis, which was more than offset by expected continued generic impacts across theremainder of the Legacy Portfolio.
• Total revenues of $13.0 billion increased 6%, or 5% Ex-FX.
◦ U.S. revenues of $9.0 billion increased 6%.
◦International revenues of $4.0 billion increased 6%, or 5% Ex-FX.*All comparisons are made versus the same period in 2025 unless otherwise stated.
SECOND QUARTER PRODUCT REVENUE HIGHLIGHTS(e)
** See "Use of Non-GAAP Financial Information".(a) Includes Abecma, Augtyro, Onureg, Inrebic, Nulojix, Empliciti and royalty revenues, including royalties received from Merck on Winrevair.(b) Includes other mature brands.(c) Includes revenue hedging activities in 2026.(d) Worldwide (WW) includes U.S. and International (Int'l).(e) For the above table and all subsequent tables, certain totals may not sum due to rounding. Percentages have been calculated using unrounded amounts.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines thathelp patients prevail over serious diseases. We are pursuing bold science to define what's possiblefor the future of medicine and the patients we serve.